tetano
Editor, Senior Moderator
Int J Infect Dis. 2019 Jul 26. pii: S1201-9712(19)30302-9. doi: 10.1016/j.ijid.2019.07.017. [Epub ahead of print]
[h=1]Comparative Epidemiology of Influenza B by Lineage in Intensive Care Unit-Admitted Patients with Complications: A Nationwide Study in Taiwan, 2013-2017.[/h] Chen HJ[SUP]1[/SUP], Su CP[SUP]2[/SUP], Liu MT[SUP]3[/SUP], Tsou TP[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] We describe the relative proportions and epidemiological features of influenza B/Victoria and B/Yamagata, using data from nationwide surveillance systems.
[h=4]METHODS:[/h] We collected respiratory samples from outpatients with influenza-like illness (ILI) and intensive care unit (ICU)-admitted patients with complications (pulmonary or neurological complications, myocarditis/pericarditis or invasive bacterial infection) for virus isolation and lineage typing. Demographics, epidemiological features, and vaccination history from ICU-admitted patients with complications were analyzed.
[h=4]RESULTS:[/h] From July 2013-June 2017, 21% of 11517 influenza isolates were influenza B. B/Victoria was the predominant circulating strain in 2013-2014, accounted for 56% of all influenza B positive samples and B/Yamagata was predominant in 2014-2017 (82%, 69%, and 85%, respectively). Among all typed viruses, the proportion of B/Yamagata was higher among specimens from ICU-admitted patients with complications (77%, 154/199) than from ILI outpatients (66%, 276/418, p < 0.005). Compared to B/Victoria, B/Yamagata infected ICU-admitted patients with complications were older, median age (71 vs 59 years, p < 0.05), had longer durations of hospitalization (15 vs 7.5 days, p < 0.05) and ICU stays (8.5 vs 5.5 days, p < 0.05).
[h=4]CONCLUSIONS:[/h] Two lineages of influenza B viruses co-circulate annually in Taiwan. Among ICU-admitted patients with complications, B/Yamagata causes more severe illness than B/Victoria.
Copyright ? 2019. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Influenza B; comparative epidemiology; lineage; lineage-mismatch; vaccine
PMID: 31357058 DOI: 10.1016/j.ijid.2019.07.017
[h=1]Comparative Epidemiology of Influenza B by Lineage in Intensive Care Unit-Admitted Patients with Complications: A Nationwide Study in Taiwan, 2013-2017.[/h] Chen HJ[SUP]1[/SUP], Su CP[SUP]2[/SUP], Liu MT[SUP]3[/SUP], Tsou TP[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] We describe the relative proportions and epidemiological features of influenza B/Victoria and B/Yamagata, using data from nationwide surveillance systems.
[h=4]METHODS:[/h] We collected respiratory samples from outpatients with influenza-like illness (ILI) and intensive care unit (ICU)-admitted patients with complications (pulmonary or neurological complications, myocarditis/pericarditis or invasive bacterial infection) for virus isolation and lineage typing. Demographics, epidemiological features, and vaccination history from ICU-admitted patients with complications were analyzed.
[h=4]RESULTS:[/h] From July 2013-June 2017, 21% of 11517 influenza isolates were influenza B. B/Victoria was the predominant circulating strain in 2013-2014, accounted for 56% of all influenza B positive samples and B/Yamagata was predominant in 2014-2017 (82%, 69%, and 85%, respectively). Among all typed viruses, the proportion of B/Yamagata was higher among specimens from ICU-admitted patients with complications (77%, 154/199) than from ILI outpatients (66%, 276/418, p < 0.005). Compared to B/Victoria, B/Yamagata infected ICU-admitted patients with complications were older, median age (71 vs 59 years, p < 0.05), had longer durations of hospitalization (15 vs 7.5 days, p < 0.05) and ICU stays (8.5 vs 5.5 days, p < 0.05).
[h=4]CONCLUSIONS:[/h] Two lineages of influenza B viruses co-circulate annually in Taiwan. Among ICU-admitted patients with complications, B/Yamagata causes more severe illness than B/Victoria.
Copyright ? 2019. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Influenza B; comparative epidemiology; lineage; lineage-mismatch; vaccine
PMID: 31357058 DOI: 10.1016/j.ijid.2019.07.017